B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus

Podolskaya, A. A.; Stadermann, Marike B.; Pilkington, Clarissa; Marks, Stephen D.; Tullus, Kjell

doi:10.1136/adc.2007.126276

Cited by 66 publications

(52 citation statements)

References 22 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Five patient experienced improvement in BILAG, renal function, and proteinuria in Marks et al (2005)'s study. In Podolskaya et al (2008)'s study, 11 (58.8%) patients achieved remission, and 7 (36.8%) patients had improved outcomes. The two studies reported five cases of herpes zoster.…”

Section: Discussionmentioning

confidence: 99%

“…Compared with adult patients, the pediatric patients always took a lower dose of rituximab. Marks et al (2005) and Podolskaya et al (2008) reported that 7 patients with median age of 14.8 years received a dose of 750 mg/m 2 (about up to 100 mg, the maximum dose was 1 g) on Days 1 and 15. The participants in Nwobi et al (2008)'s study took a dose of 188 and 375 mg/m 2 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis

Lan

Han

Chen

2012

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: To review the efficacy and safety of rituximab therapy for systemic lupus erythematosus (SLE). Methods: We searched for randomized controlled trails and observational studies that evaluated the effect of rituximab based on the systemic lupus erythematosus disease activity index (SLEDAI), British Isles lupus assessment group index (BILAG), urine protein levels, and the prednisolone dose, and had adequate data to calculate the mean, standard deviation (SD), and 95% confidence intervals, and to systematically review and meta-analyze observational studies with fixed effects model or random effects model. Results: We included 2 randomized controlled studies and 19 observational clinical studies. We summarized the data from the 19 observational studies, analyzed the heterogeneity of the literature, and then used fixed effect model or random effect model for statistical analysis. The SLEDAI, BILAG, and urine protein levels and the prednisolone dosage were decreased after rituximab treatment, and the decreases in the BILAG, urine protein levels, and the prednisolone dose were found to be significant (P<0.05), when compared with baseline level. Rituximab's adverse effects generally could be controlled with an effective dosing regimen. Conclusions: Although there are still controversies about rituximab's treatment on SLE, but our study had showed that rituximab had favorable effects on refractory lupus. The long-term efficacy and safety of rituximab require further study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis

Lan

Han

Chen

2012

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

show abstract

“…У всех пациентов отмечались высокая актив-ность заболевания с развитием жизнеугрожающих состоя-ний, низкая эффективность стандартных методов терапии. Согласно этим исследованиям предложено две схемы вве-дения РТМ, продемонстрировавшие свою эффективность и безопасность: 375 мг на 1 м 2 поверхности тела на протя-жении 4 последовательных недель либо 750 мг на 1 м 2 с ин-тервалом в 2 нед [90][91][92][93][94][95].…”

Section: рекомендация 4 при наличии гемолитической анемии показано дunclassified

Psychiatric Illness of Systemic Lupus Erythematosus in Childhood: Spectrum of Clinically Important Manifestations

Lim

Lefebvre²,

Benseler³

et al. 2012

J Rheumatol

View full text Add to dashboard Cite

Современные международные рекомендации по диагностике и лечению системной красной волчанки с ювенильным дебютом Каледа М.И., Никишина И.П.Системная красная волчанка (СКВ) с дебютом в детском и подростковом возрасте представляет существен-ную проблему в практике педиатров и ревматологов ввиду диагностических сложностей, особенностей тече-ния и большей вероятности неблагоприятного прогноза. До 20% больных СКВ заболевают в возрасте млад-ше 18 лет. Только у 13% пациентов с ювенильным дебютом во взрослом состоянии имеется безмедикамен-тозная ремиссия при более низком, чем в популяционном контроле, качестве жизни. Статья посвящена об-суждению последних международных рекомендаций по диагностике, мониторингу и лечению СКВ у детей и подростков, опубликованных в 2017 г., с комментариями, основанными на данных литературы и на прак-тическом опыте ведения подобных пациентов. Ключевые слова: системная красная волчанка; клинические рекомендации; детский возраст. Для ссылки: Каледа МИ, Никишина ИП. Современные международные рекомендации по диагностике и ле-чению системной красной волчанки с ювенильным дебютом. Научно-практическая ревматология. 2018;56(4):405-415. CURRENT INTERNATIONAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUSKaleda M.I., Nikishina I.P.Systemic lupus erythematosus (SLE) with its onset in childhood or adolescence is a significant problem in the practice of pediatricians and rheumatologists due to diagnostic difficulties, clinical features, and the greater likelihood of unfavorable prognosis. About 20% of SLE patients fall ill at the age of 18 years. Only 13% of patients with juvenile-onset SLE have a drug-free remission in adulthood and have a lower quality of life than population controls. The paper discusses the latest international guidelines for the diagnosis, monitoring, and treatment of SLE in children and adolescents, which were published in 2017, with comments based on the data available in the literature and on practical experiences in managing these patients.

show abstract

“…4 Podolskaya et al previously reported that 18 of 19 children who received two RTX infusions, at a dose of 750 mg/m 2 , achieved favorable outcomes without serious infections. 3 On the other hand, it has been reported that a schedule of four doses of RTX can be associated with serious infections in patients with refractory SLE. 1,2 Interestingly, it has been reported that treatment with a single dose of RTX (375 mg/m 2 ) may be effective and safe in children with refractory steroid-dependent nephrotic syndrome.…”

mentioning

confidence: 99%

“…[1][2][3][4] Since the safety of RTX treatment is an important concern, especially in pediatric-onset disease, the development of optimal low-dose RTX treatment strategies for refractory SLE that minimize toxicity while maintaining treatment efficacy is required. Our present clinical experience suggests that even single doses of RTX may be effective for some children with refractory SLE.…”

mentioning

confidence: 99%

Single dose of rituximab for pediatric-onset refractory systemic lupus erythematosus

Ikeda

Watanabe

Aizawa-Yashiro

et al. 2013

Lupus

View full text Add to dashboard Cite

show abstract

B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus

Abstract: In our cohort of children, rituximab was safe and effective when used in combination with standard immunosuppressive agents. Randomised controlled studies are needed to further evaluate the safety and efficacy of rituximab therapy.

Cited by 66 publications

References 22 publications

Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis

Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis

Psychiatric Illness of Systemic Lupus Erythematosus in Childhood: Spectrum of Clinically Important Manifestations

Single dose of rituximab for pediatric-onset refractory systemic lupus erythematosus

Contact Info

Product

Resources

About